An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy
Clinical trial NCT02538666 · COMPLETED
Trial details
- NCT number
- NCT02538666
- Sponsor
- Bristol-Myers Squibb
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-10-13
- Primary completion
- 2018-10-01
- Enrollment
- 907
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.